Dr. Kleiman’s research efforts, have been focused on acute coronary syndromes and coronary interventions. The bulk of this effort has been in the design, management and execution phases of clinical trials in these two fields, at both the single center and multicenter levels. As a part of this effort, he has dedicated considerable time to serving on the steering committees of several dozen multicenter trials.

Dr. Kleiman established the Applied Platelet Physiology Laboratory, where work has centered around two areas: providing clinical trials that were complemented by nested mechanistic and pathophysiologic studies, and carrying out independent physiologic studies examining issues such as aspirin dosing, platelet activation during coronary interventions, individual responses to the activity of thienopyridines, and the relation of platelet turnover and COX-2 expression to aspirin sensitivity. The laboratory has also collaborated with other labs in the Texas Medical Center, including Rice University’s Department of Bioengineering, Baylor’s Leukocyte Biology Laboratory, and most recently, the Molecular Genetics of Cardiovascular Diseases laboratory at Baylor and the stem cell group at M.D. Anderson Cancer Center. These collaborations have allowed the laboratory to expand its foci to include investigations such as the effects of P2Y12 inhibition and GP IIb/IIIa ligation on leukocyte rolling, leukocyte activation following GP IIb/IIIa administration, the role of platelet P-selectin on leukocyte membrane changes, and, most recently, the relationship between circulating endothelial precursor cells and coronary collateral vessels in patients with acute coronary syndromes.